<?xml version="1.0" encoding="UTF-8"?>
<NDC>
<NDCCode>
63379-026-01
</NDCCode>
<PackageDescription>
10 VIAL, SINGLE-USE in 1 TRAY (63379-026-01) > 20 mL in 1 VIAL, SINGLE-USE (63379-026-00)
</PackageDescription>
<NDC11Code>
63379-0026-01
</NDC11Code>
<ProductNDC>
63379-026
</ProductNDC>
<ProductTypeName>
HUMAN PRESCRIPTION DRUG
</ProductTypeName>
<ProprietaryName>
Retrovir
</ProprietaryName>
<ProprietaryNameSuffix/>
<NonProprietaryName>
Zidovudine
</NonProprietaryName>
<DosageFormName>
INJECTION, SOLUTION
</DosageFormName>
<RouteName>
INTRAVENOUS
</RouteName>
<StartMarketingDate>
20101104
</StartMarketingDate>
<EndMarketingDate/>
<MarketingCategoryName>
APPROVED DRUG PRODUCT MANUFACTURED UNDER CONTRACT
</MarketingCategoryName>
<ApplicationNumber>
NDA019951
</ApplicationNumber>
<LabelerName>
Glaxo Operations UK Ltd
</LabelerName>
<SubstanceName>
ZIDOVUDINE
</SubstanceName>
<StrengthNumber>
10
</StrengthNumber>
<StrengthUnit>
mg/mL
</StrengthUnit>
<Pharm_Classes>
Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Nucleoside Analog [Chemical/Ingredient],Nucleoside Reverse Transcriptase Inhibitors [MoA]
</Pharm_Classes>
<DEASchedule/>
<Status>
Deprecated
</Status>
<LastUpdate>
2017-12-27
</LastUpdate>
<PackageNdcExcludeFlag>
N
</PackageNdcExcludeFlag>
<ProductNdcExcludeFlag>
N
</ProductNdcExcludeFlag>
<ListingRecordCertifiedThrough>
20181231
</ListingRecordCertifiedThrough>
<StartMarketingDatePackage/>
<EndMarketingDatePackage/>
<SamplePackage/>
</NDC>